Latha Subbiah

Latha Subbiah

Auto-generated profile, based on publicly available information

Latha Subbiah

Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational Research, University College of Engineering Bharathidasan Institute of Technology Campus, Anna University, Tiruchirappalli 620024, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2019 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
SMSathish Kumar Marimuthu
Sathish Kumar Marimuthu
KNKrishnanand Nagarajan
Krishnanand Nagarajan
SPSathish kumar Perumal
Sathish kumar Perumal
SPSelvamani P
Selvamani P
LSLatha Subbiah
Latha Subbiah

1 April 2015 in Journal of Magnetism and Magnetic Materials
Verified
Journal Article
Closed access
PCPrabu Chakkarapani
Prabu Chakkarapani
LSLatha Subbiah
Latha Subbiah
SPSelvamani P
Selvamani P
ABArputha Bibiana
Arputha Bibiana
FAFredrik Ahrentorp
Fredrik Ahrentorp
Christer JohanssonChrister Johansson
Christer Johansson

1 May 2009 in Journal of Magnetism and Magnetic Materials
Verified
Journal Article
Closed access
SLSubbiah Latha
Subbiah Latha
PSPalanisamy Selvamani
Palanisamy Selvamani
CKChelladurai Senthil Kumar
Chelladurai Senthil Kumar
PSPalaniappan Sharavanan
Palaniappan Sharavanan
GSGovindan Suganya
Govindan Suganya
PRPoduri Rama Rao
Poduri Rama Rao

1 April 2017 in Journal of Magnetism and Magnetic Materials
Verified
Journal Article
Closed access
CPChakkarapani Prabu
Chakkarapani Prabu
SLSubbiah Latha
Subbiah Latha
PSPalanisamy Selvamani
Palanisamy Selvamani
FAFredrik Ahrentorp
Fredrik Ahrentorp
Christer JohanssonChrister Johansson
Christer Johansson
SOSatoshi Ota
Satoshi Ota

12 April 2021 in Current Drug Research Reviews
Verified
Journal Article
Closed access
PDF file
JSJubie Selvaraj
Jubie Selvaraj
UDUma Durai
Uma Durai
SLSubbiah Latha
Subbiah Latha
Selvaraj AyyamperumalSelvaraj Ayyamperumal
Selvaraj Ayyamperumal
AWAshish Wadhwani
Ashish Wadhwani
TPThangavelu Prabha
Thangavelu Prabha
Background: A newer trend has been seen recently to reuse the conventional drugs with distinct indications for the newer applications to speed up the drug discovery and development based on earlier records and safety data. Most of the non-cancerous agents could afford a little or tolerable side effects in individuals. However, the repositioning of these non-cancerous agents for successful anticancer therapy is an outstanding strategy for future anti-cancer drug development. Since more diverse and selective cancer drug targets are being discovered and developed, the approved drug collections are particularly useful to quickly identify clinically advanced anticancer drugs against those targets. Objective: Antihelminthic drugs such as Mebendazole and Albendazole (Benzimidazole class) have been reported to exhibit cytotoxicity (or anticancer activities) against several types of cancer. Therefore, this study aims to repurpose the benzimidazole scaffold for breast cancer treatment. Methods: In the present study, three hydrazone analogs having a benzimidazole motif in their structural frame were synthesized. Their in-silico binding studies against HER2 receptor (PDB ID: 4LQM) and ADMET studies were carried out using Accelrys drug discovery studio 4.1. Cytotoxicity of the synthesized compounds against HER2 overexpressed MCF-7 cell lines was determined by MTT assay. Results: One of the compounds 2-[2-(2,4-dinitrophenyl)hydrazinylidene]-2,3-dihydro-1H-benzimidazole (U1) has shown good cytotoxicity when compared to the standard Lapatinib, which is a well known HER2 inhibitor. Conclusion: Thus, the designed benzimidazole scaffold might serve as the best leads for treating breast cancer, which is additionally confirmed by performing their docking study via Accelrys discovery studio.

1 September 2021 in Cardiovascular & Hematological Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SLSubbiah Latha
Subbiah Latha
SPSelvamani P
Selvamani P
TPThangavelu Prabha
Thangavelu Prabha
Natural products have a unique place in the healthcare industry. The genus Commiphora emerged as a potential medicinal source with huge benefits as evidenced through its use in various traditional and modern systems of medicine. Therefore, we aimed to prepare a concise review on the pharmacological activities and the indigenous uses of various plant species belonging to the genus Commiphora along with the structural information of various active botanical ingredients present in these plants based on the published literatures and scientific reports. To collect the published literatures on Commiphora in various journals; to study and classify the available information on the pharmacological uses and chemical constituents; and to present the gathered information as a precise review to serve as a potential reference for future research. Pharmacological and phytochemical data on Commiphora plant species were collected from various journals, books, reference materials, websites including scientific databases, etc. for compilation. This review article describes the various pharmacological properties of plants of Commiphora species viz., anti-arthritic and anti-inflammatory, anti-atherogenic, antibacterial, anti-coagulant, antidicrocoeliasis, anti-epileptic, anti-fascioliasis, anti-fungal, anti-heterophyidiasis, anti-hypercholesterolemic, anti-hyperlipidemic, anti-hypothyroidism, anti-obesity, anti-osteoarthritic, antiosteoclastogenesis, anti-oxidant, anti-parasitic, anti-pyretic, anti-schistosomiasis, anti-septic, antithrombotic, anti-ulcer, cardioprotective, COX enzyme inhibitory, cytotoxic /anti-carcinogenic/anticancer, DNA cleavage, hypotensive, inhibits lipid peroxidation, inhibits NO and NO synthase production, insecticidal, local anesthetic, molluscicidal, smooth muscle relaxant, and tick repellent activities along with toxicity studies. Furthermore, the review also included various secondary metabolites isolated from various species of Commiphora genus along with their chemical structures serving as a ready resource for researchers. We conclude that the plant species belonging to the genus Commiphora possesses abundant pharmacological properties with a huge treasure of diverse secondary metabolites within themselves. This review indicates the necessity of further in-depth research, pre-clinical, and clinical studies with Commiphora genus, which may help to detect the unidentified potential of the Commiphora plant species.